SecBot SecBot
EFFECT ·Filed Mar 31, 2026

SRZNW

Surrozen, Inc./DE
BEARISH
Impact 7/10
Horizondays Processed7mo ago SEC9999999995-26-001000
IPO/offering going effective
Actionable Insight ▼ Bearish

Traders should monitor for imminent ATM share sales, which will dilute existing shareholders. The overhang of potential issuance may pressure the stock near-term, especially given the company's lack of revenue and ongoing losses.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SRZNW ▲ 0.00% at T+60d
SHORT call ✗ call lost 0.00% · α vs SPY +13.20% · entry $0.0170 → $0.0170
Entry = T+0 close
Mar 31, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.75%
$0.0170
settled 7mo ago
T+5d
0.00%
call 0.00% · α +3.94%
$0.0170
settled 7mo ago
T+20d
+49.41%
call -49.41% · α -39.99%
$0.0254
settled 6mo ago
T+60d
0.00%
call 0.00% · α +13.20%
$0.0170
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Surrozen, Inc.'s S-3 shelf registration has become effective, allowing the company to issue up to $200 million in securities, including a $50 million ATM offering. This creates a potential dilution overhang as the company may raise capital opportunistically in the near term.

Key Facts

  • S-3 shelf registration became effective on 2026-03-30
  • Authorization to issue up to $200 million in securities, including common stock, preferred stock, debt, and warrants
  • Specific $50 million ATM (at-the-market) offering registered for common stock through TD Securities
  • Proceeds to be used for general corporate purposes, including R&D funding
  • Company has a history of significant operating losses as a clinical-stage biotech

Financial Impact

Up to $200 million in potential dilution, with $50 million specifically registered for immediate ATM sales

dilutionequitycash

Risk Factors

  • Near-term dilution from ATM share sales
  • Downward pressure on stock price due to supply overhang
  • Use of proceeds for R&D without near-term revenue generation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001000
Document: 9999999995-26-001000-index.html9999999995-26-001000
Document: 9999999995-26-001000.txt9999999995-26-001000
3 reports for SRZNW
Performance horizon
Filters
Rows
Reports for SRZNW — sortable, filterable
TypeNow
May 6, 2026
24w ago
8-K
NEUTRAL ★ 4/10
$0.0170awaiting T+60——
Apr 1, 2026
29w ago
DEFA14A
NEUTRAL ★ 3/10
$0.0170 $0.0165▼ −2.94%▼ −17.10%—
Mar 31, 2026
30w ago
EFFECT
BEARISH ★ 7/10
$0.0170 $0.0170· 0.00%▲ +13.20%—
Showing 3 of 3

US Market Status

Market Open — Closes in 4h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026